Glucagon-Like Peptide 1 – Page 6

Novo Nordisk Seeks FDA Restriction on Victoza Compounding Amid Ongoing GLP-1 Supply Issues

10 months ago talkbio0Tagged Glucagon-Like Peptide 1, liraglutide, Nordisk, pharmaceutical regulation, United States Food and Drug Administration, Victoza

Novo Nordisk, FDA, Victoza, liraglutide, compounding, GLP-1, supply issues, pharmaceutical regulation

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

10 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

Eli Lilly Intervenes in Lawsuit to Block Compounded Versions of Tirzepatide Following FDA’s Shortage Resolution

10 months ago talkbio0Tagged Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, Pharmacy facility, shortage, United States Food and Drug Administration, Zepbound

Eli Lilly, tirzepatide, GLP-1 shortage, FDA, compounding pharmacies, lawsuit, Mounjaro, Zepbound

Eli Lilly’s Zepbound Receives FDA Approval as First Prescription Drug for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity

11 months ago talkbio0Tagged Approved, Glucagon-Like Peptide 1, Obesity, Sleep Apnea, Obstructive, tirzepatide, United States Food and Drug Administration, Zepbound

GLP-1, Obstructive Sleep Apnea (OSA), Obesity, Zepbound, Tirzepatide, FDA Approval, Sleep Disorder Treatment

FDA Reaffirms End of Tirzepatide Shortage, Impacting Compounders

11 months ago talkbio0Tagged Compounders, Drug Shortage, Eli, Eli Lilly, Glucagon-Like Peptide 1, Mounjaro, United States Food and Drug Administration, Zepbound

FDA, tirzepatide, GLP-1, drug shortage, compounders, Eli Lilly, Mounjaro, Zepbound

FDA Confirms Tirzepatide Availability, Compounders Express Concerns, While Semaglutide Shortage Persists

11 months ago talkbio0Tagged Availability of, Compounders, Dosage Forms, Drug Shortage, Glucagon-Like Peptide 1, semaglutide, United States Food and Drug Administration

FDA, tirzepatide, semaglutide, GLP-1 drug shortage, compounders, pharmaceutical availability

Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity

11 months ago talkbio0Tagged advancements, agonists, Chronic disease, Diabetes Mellitus, Non-Insulin-Dependent, Future, Glucagon-Like Peptide 1, Nordisk, Obesity, semaglutide

GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements

Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug

11 months ago talkbio0Tagged Benefit, cardiometabolic, Glucagon-Like Peptide 1, Hansoh Pharma, HS-10535, Merck, Obesity, Oral cavity, Weight Loss

Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits

Healthcare Evolution 2025: AI, IRA, and GLP-1s Redefine the Industry

12 months ago talkbio0Tagged advancements, Artificial Intelligence, Biopharma, DNA Integration, Glucagon-Like Peptide 1, Health care facility, Healthcare technology, Impact food supplement, Ira (eukaryote), Pharmaceutical Industry Shifts, Telemedicine, trends qualifier, Value-Based Care

AI in Healthcare, IRA Impact on Biopharma, GLP-1 Medications, Healthcare Trends 2025, Value-Based Care, Telemedicine Integration, Pharmaceutical Industry Shifts, Healthcare Technology Advancements

Metsera Secures $215M to Accelerate Obesity Drug Development

12 months ago talkbio0Tagged biotech, Glucagon-Like Peptide 1, Metabolic Diseases, Metsera, Obesity

Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease